/
Neurology
Multiple Sclerosis
125
Pipeline Programs↗
316
Active Trials↗
115
Companies Involved↗
Multiple Sclerosis is a highly competitive landscape with 125 programs across 115 companies. The most active players are Bristol-Myers Squibb, Biogen, Sanofi. 30 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical55
Phase 118
Phase 222
Phase 330
Approved
No programs
Analysis
Modality Breakdown
83%
Small molecule
85 of 103 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 103 classified programs, each share of the total. Modality classified for 93% of 125 pipeline programs.
Analysis
Trial Status
1,161
clinical trials
Completed613 · 53%
Recruiting142 · 12%
Terminated120 · 10%
Active, not recruiting100 · 9%
Not yet recruiting65 · 6%
Unknown status64 · 6%
Other57 · 5%
Clinical Trials
Trial Activity
1161 trials
Development of a Novel Functional Eye-Tracking Software Application for Multiple Sclerosis
Recruiting·—·N/A·NCT05061953·168 enrolled
Page 1 of 78
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)